Endometriosis ThoracicTORENDONCT05527002
Thoracic Endometriosis: A Cohort Study
An observational study of Endometriosis Thoracic and Endometriosis of Lung, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.
Trial summary
Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity. It is an estrogen-dependent chronic inflammatory disease. Estimates show that up to 10% of premenopausal women have endometriosis. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- Endometriosis Thoracic, Endometriosis of Lung, Endometriosis of Pleura
- What is being tested?
- Satisfaction of patients after medical and surgical treatment for thoracic endometriosis
- How many people
- 50 participants
- Where
- 1 siteItaly
- Study dates
- 1 Mar 2022to 30 Jun 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- No healthy volunteers
- Adult
Study population: All the patients referred to our endometriosis clinic and/or underwent surgery from 1 January 2000 to 01 March 2022 with a diagnosis of thoracic endometriosis were selected.
Who may be able to join
- women aged 18-50 years
- women with a diagnosis of thoracic endometriosis, in the presence or absence of other endometriotic localizations
- women referred to our tertiary-care endometriosis center " Fondazione IRCCS Ospedale Maggiore Policlinico", Milan, from 1 January 2000 to 01 March 2022.
Who cannot join
- the presence of concomitant diseases of the respiratory system
- women who denied their consensus
Trial locations and contacts
1 site in 1 country.
Italy1 site
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Milan, 20122
About this study
Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity. It is an estrogen-dependent chronic inflammatory disease. Estimates show that up to 10% of premenopausal women have endometriosis. The most frequent forms of endometriosis are superficial peritoneal implants, ovarian cysts and deep nodules or plaques. However, the pelvis is not the exclusive site of endometriotic lesions: endometriosis can also affect the diaphragm, the pleura and the lung. All these localizations are included in the spectrum of "thoracic endometriosis".
Thoracic endometriosis may present with cough, wheezing, catamenial pneumothorax, hemothorax, hemoptysis and pulmonary nodules. If the diaphragmatic pleura is also involved, catamenial periscapular or neck pain may be associated with irritation of the phrenic nerve. The symptoms of thoracic endometriosis generally have catamenial onset. Thoracic endometriosis rarely occurs isolated. It is considered a progression of pelvic endometriotic disease. Due to its varied presentation, diagnosis can be particularly difficult and often only identified due to clinical suspicion. The instrumental diagnosis of pneumothorax and catamenial hemothorax can be obtained by radiography or computerized axial tomography of the chest. Magnetic resonance imaging is to be preferred in case of diaphragmatic involvement. The gold standard remains exploratory laparoscopy, possibly accompanied by Video Assisted Thoracic Surgery (VATS).
Read more
The first-line treatment is hormone therapy, aimed at suppressing ovulation and also preventing the onset of relapses. GnRH analogues are very effective in reducing the painful symptoms associated with endometriosis, but are not superior to other first-line treatments available. Furthermore, the prolonged hypoestrogenism can cause menopausal symptoms and osteoporosis.
Surgery should be considered a second-line treatment in case of intolerance or ineffectiveness of medical therapy. The surgical approach is multidisciplinary and involves the endoscopist gynecologist and the thoracic surgeon expert in VATS.
The principal aim of the study is the retrospective evaluation of thoracic endometriosis cases in our clinic over the last 20 years in order to evaluate the effectiveness of medical and surgical treatments in terms of satisfaction of patients suffering from this clinical condition. The secondary aim is to investigate the pathogenetic aspects of this clinical condition.
Read the detailed description
Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity. It is an estrogen-dependent chronic inflammatory disease, in which the ectopic endometrium grows and proliferate under the action of estradiol. Estimates show that up to 10% of premenopausal women and 35% to 50% of women with infertility, pelvic pain or both, have endometriosis.
The most frequent forms of endometriosis are superficial peritoneal implants, ovarian cysts (endometrioma) and deep nodules or plaques (which can individually involve and infiltrate the parametria, Douglas pouch, anterior rectal wall, posterior vaginal fornix, antero-uterine pouch, bladder detrusor, ureters and sigmoid colon).
However, the pelvis is not the exclusive site of endometriotic lesions: endometriosis can also be localized outside the pelvis, resulting in the implantation and growth of an ectopic endometrium and catamenial symptoms.
In the thoracic cavity endometriosis can affect the diaphragm, the pleura and, ultimately, the lung. All these localizations are included in the spectrum of "thoracic endometriosis".
Thoracic endometriosis may present with cough, wheezing, catamenial pneumothorax, hemothorax, hemoptysis and pulmonary nodules. If the diaphragmatic pleura is also involved, catamenial periscapular or neck pain may be associated with irritation of the phrenic nerve.
Thoracic endometriosis rarely occurs isolated. It is considered a progression of pelvic endometriotic disease, due to the coexistence of pelvic localizations in up to 80% of cases and its onset at a later age (up to ten years later than pelvic endometriosis).
The diagnosis of thoracic endometriosis can be misleading, because the related symptoms can be very variable, from total asymptomaticity to catamenial pneumothorax (80%), catamenial hemothorax (14%), catamenial hemoptysis (5%) or, more rarely , appearance of pulmonary nodules.
The symptoms of thoracic endometriosis generally have catamenial onset (from 24 to 72 hours from the onset of menstrual flow), but can also appear remotely, in the event that the disease becomes chronic and the symptoms are linked to progressive clinical deterioration. Thoracic endometriosis involves the right hemithorax in 92% of cases and the left in 5% of cases; bilateral involvement occurs in only 3% of cases. Due to its varied presentation, diagnosis can be particularly difficult and often only identified due to clinical suspicion. The instrumental diagnosis of pneumothorax and catamenial hemothorax, exactly as for the non-catamenial equivalent, can be obtained by radiography or computerized axial tomography of the chest. Magnetic resonance imaging is to be preferred in case of diaphragmatic involvement; on the other hand, bronchoscopy is often not diagnostic because the endometriotic foci are located far from the mucous membranes of the main bronchi. The gold standard for the diagnosis of thoracic endometriosis remains exploratory laparoscopy, possibly accompanied by Video Assisted Thoracic Surgery (VATS). The evaluation of the presence of any diaphragmatic endometriotic implants should be routine during exploratory versus operative laparoscopy.
The first-line treatment is hormone therapy, aimed at suppressing ovulation. Medical therapy can also prevent the onset of relapses.
GnRH analogues are very effective in reducing the painful symptoms associated with endometriosis, but are not superior to other first-line treatments available. Furthermore, the prolonged hypoestrogenism can cause menopausal symptoms and osteoporosis.
Surgery should be considered a second-line treatment in case of intolerance or ineffectiveness of medical therapy. The surgical approach is multidisciplinary and involves the endoscopist gynecologist and the thoracic surgeon expert in minimally invasive surgery (VATS). Alternatively or to complete the excisional surgical treatment, in the case of pleural involvement, mechanical or chemical pleurodesis can be performed, which can reduce the risk of recurrence of pneumothorax by 20-25%.
The principal aim of the study is the retrospective evaluation of thoracic endometriosis cases in our clinic over the last 20 years in order to evaluate the effectiveness of medical and surgical treatments in terms of satisfaction of patients suffering from this clinical condition. Moreover, the secondary aim is to investigate the pathogenetic aspects of this clinical condition.
This is a case report, retrospective/prospective and monocentric study; it is based on the review of medical records and on outpatient follow-up visits of patients in our clinic with thoracic endometriosis. This is a study design that it is best suited to a low prevalence of disease.
- Conditions
- Endometriosis Thoracic, Endometriosis of Lung, Endometriosis of Pleura, Endometriosis-related Pain, Endometriosis
- Being tested
- Satisfaction of patients after medical and surgical treatment for thoracic endometriosis
- Keywords
- Medical therapy, Surgical treatment, Satisfaction
- Medical subject headings
- Endometriosis, Personal Satisfaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Satisfaction of patients after medical and surgical treatment for thoracic endometriosisOther
It is a retrospectively evaluation of cases of thoracic endometriosis in our clinic over the last 20 years, based on the review of medical records and on outpatient follow-up visits.
The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period.
If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied
a five-level Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied) to evaluate the effectiveness of medical and surgical treatments for thoracic endometriosis.
Measured: 10 years
Number of patients greatly improved, much improved, minimally improved, unchanged, minimally worsened, very worsened and greatly worsened
Patients' Global Impression of Change (PGIC) scale, a composed of seven levels (greatly improved, much improved, minimally improved, unchanged, minimally worsened, very worsened, greatly worsened) to evaluate the effectiveness of medical and surgical treatments for thoracic endometriosis.
Measured: 10 years
Number of patients with none, mild, moderate, severe or very severe symptoms
Patients' Global Impression of Severity (PGIS) scale, a scale consisting of five levels (none, mild, moderate, severe, very severe)
Measured: 10 years
Mean scores of HADS- Hospital Anxiety and Depression Scale
The HADS questionnaire is a self-assessment mood scale specifically designed for use in non-psychiatric hospital outpatients to determine states of anxiety and depression. It comprises 14 questions, 7 for the anxiety subscale and 7 for the depression subscale.
Lower scores indicate better psychological status
Measured: 10 years
Mean scores of the Short Form Survey, SF-12
The SF-12 health survey, developed from the original SF-36 questionnaire, is a well-known, validated, self-administered 12-item instrument. It measures health dimensions covering functional status, well-being, and overall health. Information from the 12 items is used to construct Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) measures, with higher scores indicating better health perception.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2022
- Study start1 Mar 2022
- Primary completion30 Jun 2022
- Study completion30 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Endometriosis ThoracicStudies of the same condition, open and under way.
- More trials run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Direzione Ginecologia, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Investigators
- Nicola Berlanda, Prof, Principal investigator, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05527002
- Sponsor's protocol ID
- 2509
- Acronym
- TORENDO
- Status last verified
- Aug 2022
- First submitted
- 1 May 2022
- Last updated
- 2 Sep 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Thoracic Endometriosis: A Cohort Study
- ClinicalTrials.gov ID
- NCT05527002
- Acronym / sponsor ID
- TORENDO / 2509
- Conditions
- Endometriosis Thoracic, Endometriosis of Lung, Endometriosis of Pleura, Endometriosis-related Pain, Endometriosis
- Keywords
- Medical therapy, Surgical treatment, Satisfaction
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoUniversity, hospital or other
- Study start
- 1 Mar 2022 (actual)
- Primary completion
- 30 Jun 2022 (actual)
- Study completion
- 30 Jun 2022 (actual)
- First posted
- 2 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity. It is an estrogen-dependent chronic inflammatory disease. Estimates show that up to 10% of premenopausal women have endometriosis. The most frequent forms of endometriosis are superficial peritoneal implants, ovarian cysts and deep nodules or plaques. However, the pelvis is not the exclusive site of endometriotic lesions: endometriosis can also affect the diaphragm, the pleura and the lung. All these localizations are included in the spectrum of "thoracic endometriosis".
Thoracic endometriosis may present with cough, wheezing, catamenial pneumothorax, hemothorax, hemoptysis and pulmonary nodules. If the diaphragmatic pleura is also involved, catamenial periscapular or neck pain may be associated with irritation of the phrenic nerve. The symptoms of thoracic endometriosis generally have catamenial onset. Thoracic endometriosis rarely occurs isolated. It is considered a progression of pelvic endometriotic disease. Due to its varied presentation, diagnosis can be particularly difficult and often only identified due to clinical suspicion. The instrumental diagnosis of pneumothorax and catamenial hemothorax can be obtained by radiography or computerized axial tomography of the chest. Magnetic resonance imaging is to be preferred in case of diaphragmatic involvement. The gold standard remains exploratory laparoscopy, possibly accompanied by Video Assisted Thoracic Surgery (VATS).
The first-line treatment is hormone therapy, aimed at suppressing ovulation and also preventing the onset of relapses. GnRH analogues are very effective in reducing the painful symptoms associated with endometriosis, but are not superior to other first-line treatments available. Furthermore, the prolonged hypoestrogenism can cause menopausal symptoms and osteoporosis.
Surgery should be considered a second-line treatment in case of intolerance or ineffectiveness of medical therapy. The surgical approach is multidisciplinary and involves the endoscopist gynecologist and the thoracic surgeon expert in VATS.
The principal aim of the study is the retrospective evaluation of thoracic endometriosis cases in our clinic over the last 20 years in order to evaluate the effectiveness of medical and surgical treatments in terms of satisfaction of patients suffering from this clinical condition. The secondary aim is to investigate the pathogenetic aspects of this clinical condition.
Detailed description
Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity. It is an estrogen-dependent chronic inflammatory disease, in which the ectopic endometrium grows and proliferate under the action of estradiol. Estimates show that up to 10% of premenopausal women and 35% to 50% of women with infertility, pelvic pain or both, have endometriosis.
The most frequent forms of endometriosis are superficial peritoneal implants, ovarian cysts (endometrioma) and deep nodules or plaques (which can individually involve and infiltrate the parametria, Douglas pouch, anterior rectal wall, posterior vaginal fornix, antero-uterine pouch, bladder detrusor, ureters and sigmoid colon).
However, the pelvis is not the exclusive site of endometriotic lesions: endometriosis can also be localized outside the pelvis, resulting in the implantation and growth of an ectopic endometrium and catamenial symptoms.
In the thoracic cavity endometriosis can affect the diaphragm, the pleura and, ultimately, the lung. All these localizations are included in the spectrum of "thoracic endometriosis".
Thoracic endometriosis may present with cough, wheezing, catamenial pneumothorax, hemothorax, hemoptysis and pulmonary nodules. If the diaphragmatic pleura is also involved, catamenial periscapular or neck pain may be associated with irritation of the phrenic nerve.
Thoracic endometriosis rarely occurs isolated. It is considered a progression of pelvic endometriotic disease, due to the coexistence of pelvic localizations in up to 80% of cases and its onset at a later age (up to ten years later than pelvic endometriosis).
The diagnosis of thoracic endometriosis can be misleading, because the related symptoms can be very variable, from total asymptomaticity to catamenial pneumothorax (80%), catamenial hemothorax (14%), catamenial hemoptysis (5%) or, more rarely , appearance of pulmonary nodules.
The symptoms of thoracic endometriosis generally have catamenial onset (from 24 to 72 hours from the onset of menstrual flow), but can also appear remotely, in the event that the disease becomes chronic and the symptoms are linked to progressive clinical deterioration. Thoracic endometriosis involves the right hemithorax in 92% of cases and the left in 5% of cases; bilateral involvement occurs in only 3% of cases. Due to its varied presentation, diagnosis can be particularly difficult and often only identified due to clinical suspicion. The instrumental diagnosis of pneumothorax and catamenial hemothorax, exactly as for the non-catamenial equivalent, can be obtained by radiography or computerized axial tomography of the chest. Magnetic resonance imaging is to be preferred in case of diaphragmatic involvement; on the other hand, bronchoscopy is often not diagnostic because the endometriotic foci are located far from the mucous membranes of the main bronchi. The gold standard for the diagnosis of thoracic endometriosis remains exploratory laparoscopy, possibly accompanied by Video Assisted Thoracic Surgery (VATS). The evaluation of the presence of any diaphragmatic endometriotic implants should be routine during exploratory versus operative laparoscopy.
The first-line treatment is hormone therapy, aimed at suppressing ovulation. Medical therapy can also prevent the onset of relapses.
GnRH analogues are very effective in reducing the painful symptoms associated with endometriosis, but are not superior to other first-line treatments available. Furthermore, the prolonged hypoestrogenism can cause menopausal symptoms and osteoporosis.
Surgery should be considered a second-line treatment in case of intolerance or ineffectiveness of medical therapy. The surgical approach is multidisciplinary and involves the endoscopist gynecologist and the thoracic surgeon expert in minimally invasive surgery (VATS). Alternatively or to complete the excisional surgical treatment, in the case of pleural involvement, mechanical or chemical pleurodesis can be performed, which can reduce the risk of recurrence of pneumothorax by 20-25%.
The principal aim of the study is the retrospective evaluation of thoracic endometriosis cases in our clinic over the last 20 years in order to evaluate the effectiveness of medical and surgical treatments in terms of satisfaction of patients suffering from this clinical condition. Moreover, the secondary aim is to investigate the pathogenetic aspects of this clinical condition.
This is a case report, retrospective/prospective and monocentric study; it is based on the review of medical records and on outpatient follow-up visits of patients in our clinic with thoracic endometriosis. This is a study design that it is best suited to a low prevalence of disease.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- All the patients referred to our endometriosis clinic and/or underwent surgery from 1 January 2000 to 01 March 2022 with a diagnosis of thoracic endometriosis were selected.
Key inclusion criteria (3 listed)
- women aged 18-50 years
- women with a diagnosis of thoracic endometriosis, in the presence or absence of other endometriotic localizations
- women referred to our tertiary-care endometriosis center " Fondazione IRCCS Ospedale Maggiore Policlinico", Milan, from 1 January 2000 to 01 March 2022.
Key exclusion criteria (2 listed)
- the presence of concomitant diseases of the respiratory system
- women who denied their consensus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Satisfaction of patients after medical and surgical treatment for thoracic endometriosisIt is a retrospectively evaluation of cases of thoracic endometriosis in our clinic over the last 20 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study. | Other | – |
Primary outcome
Number of patients very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied
Time frame: 10 years
a five-level Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied) to evaluate the effectiveness of medical and surgical treatments for thoracic endometriosis.
Number of patients greatly improved, much improved, minimally improved, unchanged, minimally worsened, very worsened and greatly worsened
Time frame: 10 years
Patients' Global Impression of Change (PGIC) scale, a composed of seven levels (greatly improved, much improved, minimally improved, unchanged, minimally worsened, very worsened, greatly worsened) to evaluate the effectiveness of medical and surgical treatments for thoracic endometriosis.
Number of patients with none, mild, moderate, severe or very severe symptoms
Time frame: 10 years
Patients' Global Impression of Severity (PGIS) scale, a scale consisting of five levels (none, mild, moderate, severe, very severe)
Mean scores of HADS- Hospital Anxiety and Depression Scale
Time frame: 10 years
The HADS questionnaire is a self-assessment mood scale specifically designed for use in non-psychiatric hospital outpatients to determine states of anxiety and depression. It comprises 14 questions, 7 for the anxiety subscale and 7 for the depression subscale. Lower scores indicate better psychological status
Mean scores of the Short Form Survey, SF-12
Time frame: 10 years
The SF-12 health survey, developed from the original SF-36 questionnaire, is a well-known, validated, self-administered 12-item instrument. It measures health dimensions covering functional status, well-being, and overall health. Information from the 12 items is used to construct Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) measures, with higher scores indicating better health perception.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2022.
Related trials for Endometriosis Thoracic
Recruiting
Stanford Program to Accelerate Robotic Children's Surgery
Sleeve Gastrectomy, Cholecystectomy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicola Berlanda, Prof principal investigator
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Endometriosis Thoracic and Endometriosis of Lung, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied (time frame: 10 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2022.